Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

equecabtagene autoleucel

A preparation of autologous T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) with a fully human single chain variable fragment (scFv) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, equecabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells, and plays a key role in plasma cell proliferation and survival.
Synonym:autologous anti-BCMA CAR T cells CT103A
autologous anti-BCMA CAR-T cells CT103A
autologous anti-BCMA CAR-transduced T cells CT103A
autologous anti-BCMA CAR-transduced T cells CT103A
Code name:CT 103A
CT-103A
CT103A
Search NCI's Drug Dictionary